Last deal

$3M

Amount

Venture - Series Unknown

Stage

01.01.2017

Date

3

all rounds

$18.48M

Total amount

date founded

Financing round

General

About Company
Remedy Pharmaceuticals is developing drugs to treat life-threatening brain edema-related conditions.

Industry

Sector :

Subsector :

founded date

01.01.2004

Number of employees

Company Type

For Profit

Last funding type

Venture - Series Unknown

IPO status

Private

Description

The company focuses on addressing the significant medical need for effective therapies in managing brain swelling, which is associated with high mortality and morbidity. Their drugs target NCCa-ATP channels in acute central nervous system injuries, including traumatic brain injuries, strokes, and spinal cord injuries. Remedy Pharmaceuticals aims to transform the treatment of these conditions and has a particular focus on CNS-related edema in critical care indications such as subarachnoid hemorrhage, intracerebral hemorrhage, and cardiac arrest.
Contacts
Similar Companies
1000
RespireRx Phamaceuticals

RespireRx Phamaceuticals

RespireRx Pharmaceuticals discovers and develops drug therapies for sleep apnea and CNS disorders.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Glen Rock, NJ 07452, USA

total rounds

5

total raised

$12.21M
Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Pharmaceuticals, Health Care

Location

San Diego, CA, USA

total rounds

14

total raised

$811.73M
Chase Pharmaceuticals

Chase Pharmaceuticals

Chase Pharmaceuticals develops improved treatments for CNS diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Washington Cir NW, Washington, DC, USA

total rounds

4

total raised

$28.7M
Avanir Pharmaceuticals

Avanir Pharmaceuticals

Avanir Pharmaceuticals is a biopharmaceutical company that provides innovative medicines to patients with central nervous system disorders.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Aliso Viejo, CA, USA

total rounds

2

total raised

$46.2M
M&A Details
1

Transaction name

Acquired by

Biogen

announced date

18.05.2017

price

$120M

Financials

Funding Rounds
6
3

Number of Funding Rounds

$18.48M

Money Raised

Their latest funding was raised on 01.01.2017. Their latest round Venture - Series Unknown

Date 
Funding Round 
Investors 
Money Raised 
Lead 

Vertical GP-5

Company

count Of Investments

1

count Of Exists

1
Broadview Ventures

Broadview Ventures

Broadview Ventures invests in technology solutions for cardiovascular and neurovascular diseases.

Sector

Medical Equipment and Services

Subsector

Medical Equipment

Keywords

Health Care

Location

Boston, MA, USA

count Of Investments

66

count Of Exists

3
Co-Investors
Investors
2
2

Number of lead investors

2

Number of investors

Investor 
Lead 
Round 
Partners 
Yes
Venture - Series Unknown

Vertical GP-5

Company

count Of Investments

1

count Of Exists

1
Broadview Ventures

Broadview Ventures

Broadview Ventures invests in technology solutions for cardiovascular and neurovascular diseases.

Sector

Medical Equipment and Services

Subsector

Medical Equipment

Keywords

Health Care

Location

Boston, MA, USA

count Of Investments

66

count Of Exists

3
Frederick Jones

Frederick Jones

current job

BioAdvance
BioAdvance

People

Founders
2
Sven M. Jacobson
Sven M. Jacobson

Sven M. Jacobson

Sven is a co-founder of Remedy Pharmaceuticals. He has been the CEO of Remedy since 2007 and serves on the company’s board of directors. He is the inventor of CIRARA’s formulation and the company’s MPD technology. Sven has over 20 years of senior management experience. Sven is a Partner at Carrot Capital Healthcare Ventures and co-founder and board member of Critical Diagnostics, a diagnostics company focused on cardiac disease. Sven was also a co-founder of Access Scientific, which was acquired by Endeavour Capital, as well as Cure Therapeutics, and St. Camillus Medical. He has experience in the neurocritical care, neurology, cardiovascular, orthopedic, and vascular access fields. Sven’s international experience includes prior executive management positions at Leisureplanet (Belgium) and Rennies Travel and Financial Services Group (South Africa), and current board membership of Critical Diagnostics Ltd. (Ireland). Sven received his Bachelor of Science Engineering (BSc Eng) and MBA degrees from the University of the Witwatersrand in Johannesburg, South Africa.

current job

Woolsey Pharmaceuticals
Woolsey Pharmaceuticals

organization founded

4

Sven M. Jacobson

David M. Geliebter
David M. Geliebter

David M. Geliebter

David is a co-founder of Remedy Pharmaceuticals. A serial entrepreneur, he has over 50 years of experience successfully starting and growing several businesses. David founded and ran the Carson Group, a global financial information and advisory company, which was sold to Thomson Corporation in 2000. He was also a founding principal and President of Evolution Capital, a healthcare investment banking firm. Prior to that, David founded Harvard Capital, a financial communications company that was acquired by WPP Group in 1986. David is the Managing Partner of Carrot Capital Healthcare Ventures and founder and board member of Critical Diagnostics, a diagnostics company focused on cardiac disease. David is a past winner of the Ernst & Young Entrepreneur of the Year Award.

current job

Woolsey Pharmaceuticals
Woolsey Pharmaceuticals

organization founded

6

David M. Geliebter

Employee Profiles
4
Thomas MacAllister

Thomas MacAllister

Vice President of R&D

David M. Geliebter

David M. Geliebter

Executive Chairman & Co-Founder

Ann Tunstall

Ann Tunstall

VP, Regulatory And Clinical Operations

Sven M. Jacobson

Sven M. Jacobson

CEO, Co-Founder

Activity

Recent News
0